Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections
Nicholas Rebold, Taylor Morrisette, Abdalhamid M Lagnf, Sara Alosaimy, Dana Holger, Katie E. Barber, Julie Ann Justo, Kayla Antosz, Travis J Carlson, Jeremy J Frens, Mark Biagi, Wesley D. Kufel, William J Moore, Nicholas J. Mercuro, Brian R. Raux, Michael J. Rybak
Abstract
Abstract A multicenter case series of 21 patients were treated with imipenem-cilastatin-relebactam. There were mixed infection sources, with pulmonary infections (11/21,52%) composing the majority. The primary pathogen was Pseudomonas aeruginosa (16/21, 76%), and 15/16 (94%) isolates were multidrug-resistant. Thirty-day survival occurred in 14/21 (67%) patients. Two patients experienced adverse effects.
Topics & Concepts
MedicineImipenem/cilastatinImipenemGramGram-negative bacterial infectionsPathogenic organismMultiple drug resistanceCilastatinMicrobiologyTigecyclineAntibioticsAntibiotic resistanceBacteriaBiologyGeneticsAntibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacyTuberculosis Research and Epidemiology